Guidance for industry on flexible approaches to regulation the Medicines and Healthcare Agency (MHRA) are taking during the COVID-19 outbreak.
The MHRA are working closely with the Department of Health and Social Care (DHSC) and other healthcare partners and stakeholders to rapidly develop a package of ‘flexibilities’ to regulatory guidance, in order to support the medicines supply chain and wider healthcare response to the COVID-19 outbreak in the UK.
These regulatory flexibilities are:
See the full guidance here.
We are all navigating uncharted waters as business and society faces up to the impact of COVID-19. We very much hope you and your loved ones remain in good health.
Please be assured that Fieldfisher is continuing to work with clients to navigate COVID-19 related issues and on business as usual needs. Do get in touch with us if you would like to chat anything through.
These regulatory flexibilities are:
- temporary and will be kept under review, except where regulatory extensions have been stated
- offered to provide flexibility in exceptional circumstances
- effective immediately
See the full guidance here.
We are all navigating uncharted waters as business and society faces up to the impact of COVID-19. We very much hope you and your loved ones remain in good health.
Please be assured that Fieldfisher is continuing to work with clients to navigate COVID-19 related issues and on business as usual needs. Do get in touch with us if you would like to chat anything through.